An SBOM, or software bill of materials, is a structured inventory of the software components in a product. For a medical device, it becomes useful when the team can connect that inventory to the specific device version, configuration, interfaces, controls, and patient or clinical consequences that matter. It is not a cybersecurity conclusion. It is the starting point for making one quickly and responsibly.
A component list is easy to underestimate until a vulnerability report arrives. A supplier notice may name a library, operating system, or open-source package that appears to be relevant. The real question is more demanding: is that component in this released device, is the affected function enabled, can the reported weakness be reached in the actual use environment, and could it affect safe or effective use? A current software bill of materials helps a team begin with facts instead of rebuilding the product history under pressure.
FDA's cybersecurity FAQs for medical devices state that applicable premarket submissions for cyber devices must include specified cybersecurity information, including an SBOM. The useful response is not to produce a last-minute spreadsheet. It is to build an inventory that supports the cybersecurity evidence, quality decisions, and post-market work the product will need throughout its lifecycle.
Start With the Decision the SBOM Must Support
An SBOM should help a device team make a better decision when new information arrives. That means the record needs a clear purpose before the team decides on a format or a tool. In practice, it should help answer four questions: what software is in a released product, where and how it is used, which product versions may be affected by a reported issue, and who can assess and act on the information.
The same inventory can support premarket evidence, supplier oversight, release control, and a post-market vulnerability response. But it only does that if it reflects the product that was actually built. A list copied from a development environment can be misleading when a component was removed before release, a feature is disabled in production, or different configurations were delivered to different customers.
Begin with the product boundary. Include the device software, operating system, libraries, firmware, cloud services, mobile applications, support tools, accessories, and external components that can materially affect the device's security or operation. The broader medical device cybersecurity planning guide helps teams define that boundary before the inventory becomes a disconnected technical artifact.
Capture the Component Details That Make Investigation Possible
A useful SBOM identifies each component precisely enough to distinguish it from a similarly named package and to determine whether a reported vulnerability could apply. At a minimum, teams normally need the component name, version, supplier or author, dependency relationship, and a stable identifier where one is available. They also need a way to tie that component list to the released device, software build, and configuration.
The National Telecommunications and Information Administration's minimum elements for an SBOM provide a practical baseline: component data, automation support, and practices for keeping information available over time. For medical-device teams, the point is not to adopt a generic inventory without thought. It is to retain enough consistent information that the team can recognize a component, locate it in a product, and understand what release or dependency context applies.
Avoid a common trap: recording only the names of direct dependencies. A vulnerability can affect a component brought into the product indirectly through another package, operating system image, framework, or third-party service. The inventory should make those relationships visible enough for the product team to investigate without relying on a single developer's memory.
Choose a Format That Fits the Program
The format should support the way the organization builds, reviews, and maintains the device. A machine-readable SBOM can make it easier to compare component inventories, monitor supplier information, and respond to a large volume of security notices. A clear human-readable view can help a cross-functional team review what is in a release and understand the relationship between components, product versions, and owners. Many programs need both forms for different decisions.
Do not let the format decision become a substitute for product judgment. A structured file can be complete in a technical sense and still be difficult for quality, regulatory, service, or leadership teams to use. The right approach gives each group a reliable way to answer the question in front of it without creating competing inventories. Establish a controlled source, define who reviews changes, and decide which release events trigger a new or updated record.
The process should also account for software supplied through cloud services, operating-system images, platform providers, and contractors. Not every supplier will deliver information in the same format or on the same timetable. What matters is that the manufacturer can identify the product dependency, evaluate the information received, and preserve the evidence needed to support a released device. That is a supplier and quality-system responsibility as much as a cybersecurity task.
Link the Inventory to the Released Configuration
The difference between a useful SBOM and a static list is release context. A component may be present in a source repository but excluded from a particular build. A vulnerable capability may be available in a package but disabled in the released configuration. A device installed in a hospital may have a different communication path from the same product used in a home setting. Without context, the team can only say that a component name appears somewhere in its development records.
Connect the SBOM to the device model, software version, build or release identifier, relevant configuration, and delivery channel. When a vulnerability is announced, that connection lets the team ask which deployed units may be affected and whether the affected code path is actually present. It also creates a clean handoff between engineering, quality, regulatory, service, and customer-facing teams.
This is where disciplined medical device quality consulting can add real value. The inventory must agree with change control, supplier records, configuration management, verification, and release approval. A technically correct document that cannot be reconciled with released product records will be difficult to use during an audit, a submission review, or a real field issue.
Review the SBOM Before a Submission or Major Release
Before a premarket submission, design review, significant software release, or connected-feature launch, look at the SBOM as part of the complete product record. Confirm that it reflects the current device boundary and that the listed components are tied to a specific release. Check whether the people who own software, quality, supplier information, service, and cybersecurity can explain how the inventory is produced and maintained.
Then test the questions the inventory should make easy. Can the team identify the component versions in a released device? Can it distinguish a development dependency from a deployed one? Can it trace a third-party package through an indirect dependency? Can it tell whether an affected function is enabled in the configuration a customer uses? Can it locate the decision and verification record for a material change? Any uncertainty is a practical gap worth resolving before the next external review or field event.
This review is especially useful when the device program is approaching a 510(k), De Novo, PMA, or significant post-market change. The inventory does not replace the broader cybersecurity package, but it should agree with the architecture, threat model, risk analysis, design controls, test evidence, labeling, and lifecycle plan. When those records use different product versions or assumptions, the team can spend valuable time reconciling documents instead of answering the question that prompted the review.
Do Not Treat an SBOM as the Risk Assessment
An SBOM helps answer whether a component may be present. It does not establish whether a vulnerability is exploitable in the device, what controls already reduce the exposure, or what the consequence would be for a patient, user, clinician, or healthcare organization. Those are device-specific questions that require the system boundary, intended use, architecture, and risk-management process.
For example, a reported vulnerability may require network access, a particular protocol, local administrative privileges, or an optional function that the device does not use. In other cases, a modest technical weakness may deserve urgent attention because it could alter a therapy setting, delay an alarm, corrupt a diagnostic result, or prevent an essential function. The component's published severity is useful evidence, not the final decision.
The medical device threat-modeling guide offers a practical way to bridge that gap. Trace the component through the relevant interface, the asset at risk, the conditions an attacker would need, the safeguards already in place, and the realistic consequence to device operation. That work turns a component inventory into a defensible risk decision.
Build the SBOM Into Design and Verification Work
The most dependable time to create an SBOM is while the product is being designed and assembled, not when a submission deadline is approaching. Build and release processes can often capture component information at the point where versions and dependencies are known. The team then needs a controlled way to review the output, resolve gaps, and maintain the relationship to the released device configuration.
This approach also strengthens verification. If the device relies on a secure update mechanism, the evidence should show that only intended software can be installed and that the resulting version can be identified. If a third-party component supports a connected interface, verification should address the controls and failure behavior that make the interface safe in the product's actual environment. An SBOM gives the team an inventory, while verification demonstrates that the selected product controls work.
NIST's guidance on SBOM and cybersecurity risk management makes the same distinction: component transparency can improve risk decisions, but it does not remove the need for contextual analysis and risk management. Teams preparing a submission can connect that evidence to Qualira's 510(k) submission consulting support when cybersecurity and the larger technical documentation package need to hold together.
Use the SBOM to Speed Up Vulnerability Response
The test of an SBOM happens after release, when the team receives a vulnerability notification. A good response begins by confirming the report, identifying the component and versions it concerns, and comparing that information to the released inventory. The team can then determine which device versions need further assessment and which do not.
From there, assess the actual exposure. Is the affected function enabled? Can it be reached through the product's interfaces and use environment? What access, credentials, equipment, or conditions would be required? What controls limit the path? Could the event affect confidentiality, integrity, availability, safety, or clinical workflow? The answer may be to monitor, issue a mitigation, plan an update, or take immediate action. The rationale should be visible and proportionate to the device.
Qualira's medical device vulnerability management guide walks through that response cycle in detail. It is the natural companion to an SBOM because the inventory helps the team find a possible issue, while the lifecycle process determines what the manufacturer should actually do about it.
Keep Ownership and Supplier Information Clear
A component inventory often crosses organizational boundaries. Software engineering may understand a package or dependency. Quality may own the controlled records. Regulatory may need to understand the submission impact. Service and support may know which configurations are in the field. Suppliers may provide information about components or third-party services. The SBOM process should name how those groups contribute and who owns the final record for each released product.
Supplier information deserves particular attention. A component may be commercially supported, open-source, embedded in a platform, or delivered through a managed service. The team should be able to identify the source of component information, any relevant licensing or support constraints, and the path for receiving security notices. That does not mean every supplier relationship looks the same. It means the manufacturer has a practical route to investigate and act when a dependency changes or a concern is reported.
How Qualira Helps Turn Inventory Into Usable Evidence
An SBOM is most valuable when it supports the decisions around it. Qualira helps medical-device teams connect component inventory to cybersecurity strategy, product architecture, risk management, design controls, verification, quality-system practices, premarket planning, and post-market response. The result is not simply a list of parts. It is a clearer way to understand the product and act when a security question matters.
Explore Qualira's medical device cybersecurity consulting and regulatory consulting support, or talk with the team when an SBOM, component, or vulnerability question is complicating an important product decision.
Frequently asked questions
Does FDA require an SBOM for every medical device?
The need for cybersecurity information depends on the device and the submission. FDA explains that applicable premarket submissions for cyber devices must include specified cybersecurity information, including an SBOM. Teams should assess the device's connectivity, software, interfaces, and cybersecurity risk early enough to determine what evidence is appropriate.
What should a medical device SBOM include?
A useful SBOM identifies the software components in the released product, their versions, relevant supplier or author information, and enough product context to determine where a component is used. The record should be traceable to the device configuration rather than existing as an unconnected component list.
Is an SBOM enough for medical device cybersecurity compliance?
No. An SBOM helps a manufacturer identify components when a vulnerability is reported, but it does not show whether an issue is reachable, how it could affect the device, which controls reduce the risk, or whether a change has been verified. It needs to work alongside threat modeling, risk management, design controls, verification, and post-market processes.
How often should a medical device SBOM be updated?
Update the SBOM whenever a released software component, version, dependency, configuration, or relevant connected service changes. The practical goal is to keep it aligned with the product the customer is actually using, so the team can assess a future vulnerability without reconstructing the release history.
